Choosing a PDMO^® for your programme

Infographic1 min read 19th Jul 2021

Share via email Share via LinkedIn

Choosing a PDMO® for your programme

Share via email Share via LinkedIn

Popular articles

News2 min read

Sterling receives validation from SBTi for its emission reduction targets Read more

7 min read

Why pharmaceutical manufacturing strategy should look ahead to patent expiry Read more

Scientist in Sterling labs using equipment used during radiochemistry projects

6 min read

Why radiolabelling should be part of your early drug development strategy Read more

Sterling Pharma Solutions' new analytical lab for ADCs and bioconjugation following recent investment at its Deeside, Wales facility

News2 min read

Sterling Expands ADC Manufacturing Capacity and Capabilities Read more

Scientist in Sterling's analytical laboratories

Blog6 min read

Unlock the UK-US tariff advantage: What it means for you Read more

Poster Presentation3 min read

Lost in translation: Platform analysis of an antibody oligonucleotide conjugate Read more

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

Phone

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.
VAT number: GB320549229